Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $37.8 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 4.45% year-over-year to $37.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (up 4.45% YoY) and the FY2025 annual result came in at $43.5 million, up 22.94% from the prior year.
• Other Non-Current Liabilities slipped to $37.8 million in Q1 2026 per IMDX's latest filing, from $43.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $49.6 million in Q3 2024 and troughed at $2.0 million in Q2 2024.
• A 5-year average of $24.1 million and a median of $35.3 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities sank 80.0% in 2022, then surged 2064.41% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $5.4 million in 2022, then jumped by 648.12% to $40.2 million in 2023, then dropped by 12.02% to $35.3 million in 2024, then rose by 22.94% to $43.5 million in 2025, then dropped by 13.0% to $37.8 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $37.8 million, $43.5 million, and $43.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.